Financial
Latest full-year results from official filings.
FY2026 revenue $5.65bn (+9.9%); operating margin 33.4%; net income $1.52bn.
Cash $1.47bn; debt $659.4m.
- Official results release · ResMed · 30 Jun 2026
ResMed: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Not yet researched.
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
Not yet researched.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Not yet researched.
Contract performance
Contract delivery, go-lives, terminations and disputes.
Not yet researched.